Cannabidiol reduces lipopolysaccharide‐induced nociception via endocannabinoid system activation
Basic & Clinical Pharmacology & Toxicology · 2023
DOI: 10.1111/bcpt.13876 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, 2023. Written by Rafaela Silva Dos Santos and 6 co-authors. Institution: Sciences of Motricity Institute, Federal University of Alfenas, Alfenas, Brazil. Major MEDLINE topics: Cannabidiol. Cited 10 times so far (Crossref); 60 references. Funded by: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, National Council for the Improvement of Higher Education.
Abstract (original language)
Bacterial infections are often accompanied by fever and generalized muscle pain. However, the treatment of pain with an infectious aetiology has been overlooked. Thus, we investigated the impact of cannabidiol (CBD) in bacterial lipopolysaccharide (LPS)‐induced nociception. Male Swiss mice received intrathecal (i.t.) LPS injection, and the nociceptive threshold was measured by the von Frey filaments test. Spinal involvement of the cannabinoid CB 2 receptor, toll‐like receptor 4 (TLR4), microglia and astrocytes were evaluated by i.t. administration of their respectively antagonists or inhibitors. Western blot, immunofluorescence, ELISA and liquid chromatography‐mass spectrometry were used to assess Cannabinoid CB 2 receptors and TLR4 spinal expression, proinflammatory cytokines and endocannabinoid levels. CBD was administered intraperitoneally at 10 mg/kg. The pharmacological assay demonstrated TLR4 participation in LPS‐induced nociception. In addition, spinal TLR4 expression and proinflammatory cytokine levels were increased in this process. CBD treatment prevented LPS‐induced nociception and TLR4 expression. AM630 reversed antinociception and reduced CBD‐induced endocannabinoids up‐regulation. Increased spinal expression of the cannabinoid CB 2 receptor was also found in animals receiving LPS, which was accompanied by reduced TLR4 expression in CBD‐treated mice. Taken together, our findings indicated that CBD is a potential treatment strategy to control LPS‐induced pain by attenuating TLR4 activation via the endocannabinoid system.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Sciences of Motricity Institute, Federal University of Alfenas, Alfenas, Brazil.
- Department of Pharmacology, Medical School of Ribeirão Preto, University of Sao Paulo, São Paulo, Brazil.
- Faculty of Pharmaceutical Sciences of Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
- Department of Pharmacology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
ORCID profiles: Giovane Galdino
Funding
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- National Council for the Improvement of Higher Education
Cite
APA
Dos Santos, R. S., Veras, F. P., Netto, G. P., Sorgi, C. A., Faccioli, L. H., Vilela, L. R., & Galdino, G. (2023). Cannabidiol reduces lipopolysaccharide‐induced nociception via endocannabinoid system activation. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13876
Vancouver
Dos Santos RS, Veras FP, Netto GP, Sorgi CA, Faccioli LH, Vilela LR, et al. Cannabidiol reduces lipopolysaccharide‐induced nociception via endocannabinoid system activation. Basic & Clinical Pharmacology & Toxicology. 2023. doi:10.1111/bcpt.13876
BibTeX
@article{DosSantos2023,
author = {Dos Santos, Rafaela Silva and Veras, Flávio Protassio and Netto, Gonçalves Pedro and Sorgi, Carlos Arterio and Faccioli, Lúcia Helena and Vilela, Luciano Rezende and Galdino, Giovane},
title = {Cannabidiol reduces lipopolysaccharide‐induced nociception via endocannabinoid system activation},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
doi = {10.1111/bcpt.13876}
}
EUVIMED